Incidence and Outcomes of SARS-CoV-2 Infection in Older Adults Living with Dementia: A Population-Based Cohort Study.
Administrative databases
Alzheimer’s disease
COVID-19
SARS-CoV-2 infection
cohort study
dementia
prognostic factors
Journal
Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863
Informations de publication
Date de publication:
2022
2022
Historique:
pubmed:
2
8
2022
medline:
21
9
2022
entrez:
1
8
2022
Statut:
ppublish
Résumé
The identification of risk factors for SARS-CoV-2 infection and mortality in patients with dementia is a key aspect to support clinical decisions and public health interventions. To assess the incidence of SARS-CoV-2 infection and COVID-19 related death in a cohort of patients with dementia residing in the Lazio region and to investigate predicting factors for both infection and mortality. This population-based study used information from administrative databases and the SARS-CoV-2 infection surveillance system. Patients with dementia (age ≥65) were enrolled as of December 31, 2019 and followed-up until February 28, 2021. Cumulative risk of infection and death within 60 days of infection onset, and age-standardized incidence (SIR) and mortality (SMR) ratios were calculated. Logistic regression models were applied to identify factors associated with infection and mortality. Among 37,729 dementia patients, 2,548 had a diagnosis of SARS-CoV-2 infection. The crude risk of infection was 6.7%. An increase in risk of infection was observed both in women (SIR 1.72; 95% CI 1.64-1.80) and men (SIR 1.43; 95% CI 1.33-1.54). Pneumonia, cerebrovascular and blood diseases, femur fracture, anxiety, antipsychotic and antithrombotic use were associated with an increased risk of infection. The crude risk of death was 31.0%, the SMRs 2.32 (95% CI 2.05-2.65) for men, and 2.82 (95% CI 2.55-3.11) for women. Factors associated with mortality included: male gender, age ≥85, symptoms at the diagnosis, antipsychotic and systemic antibiotics treatment. These findings emphasize the need of close and tailored monitoring of dementia patients to reduce the impact of COVID-19 on this fragile population.
Sections du résumé
BACKGROUND
The identification of risk factors for SARS-CoV-2 infection and mortality in patients with dementia is a key aspect to support clinical decisions and public health interventions.
OBJECTIVE
To assess the incidence of SARS-CoV-2 infection and COVID-19 related death in a cohort of patients with dementia residing in the Lazio region and to investigate predicting factors for both infection and mortality.
METHODS
This population-based study used information from administrative databases and the SARS-CoV-2 infection surveillance system. Patients with dementia (age ≥65) were enrolled as of December 31, 2019 and followed-up until February 28, 2021. Cumulative risk of infection and death within 60 days of infection onset, and age-standardized incidence (SIR) and mortality (SMR) ratios were calculated. Logistic regression models were applied to identify factors associated with infection and mortality.
RESULTS
Among 37,729 dementia patients, 2,548 had a diagnosis of SARS-CoV-2 infection. The crude risk of infection was 6.7%. An increase in risk of infection was observed both in women (SIR 1.72; 95% CI 1.64-1.80) and men (SIR 1.43; 95% CI 1.33-1.54). Pneumonia, cerebrovascular and blood diseases, femur fracture, anxiety, antipsychotic and antithrombotic use were associated with an increased risk of infection. The crude risk of death was 31.0%, the SMRs 2.32 (95% CI 2.05-2.65) for men, and 2.82 (95% CI 2.55-3.11) for women. Factors associated with mortality included: male gender, age ≥85, symptoms at the diagnosis, antipsychotic and systemic antibiotics treatment.
CONCLUSION
These findings emphasize the need of close and tailored monitoring of dementia patients to reduce the impact of COVID-19 on this fragile population.
Identifiants
pubmed: 35912744
pii: JAD220369
doi: 10.3233/JAD-220369
pmc: PMC9535569
doi:
Substances chimiques
Anti-Bacterial Agents
0
Antipsychotic Agents
0
Fibrinolytic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
681-693Références
Lancet Psychiatry. 2020 Dec;7(12):1054-1063
pubmed: 33031760
Geriatr Nurs. 2021 Sep-Oct;42(5):983-992
pubmed: 34256158
Int J Environ Res Public Health. 2021 May 26;18(11):
pubmed: 34073437
Front Public Health. 2021 Jul 16;9:669209
pubmed: 34336767
Alzheimers Dement. 2021 Nov;17(11):1818-1831
pubmed: 33881211
J Alzheimers Dis. 2019;70(s1):S165-S186
pubmed: 31306123
Front Neurol. 2021 Jul 22;12:692662
pubmed: 34367054
Front Immunol. 2021 Aug 18;12:680845
pubmed: 34484179
Healthcare (Basel). 2021 Jul 15;9(7):
pubmed: 34356269
Alzheimers Dement. 2021 Aug;17(8):1297-1306
pubmed: 33559975
PLoS One. 2021 Feb 3;16(2):e0246548
pubmed: 33534870
Front Public Health. 2021 Aug 09;9:684112
pubmed: 34434913
Neurology. 2021 Apr 27;96(17):e2220-e2230
pubmed: 33741639
J Glob Health. 2021 Mar 01;11:10001
pubmed: 33767855
Lancet Reg Health Eur. 2022 Jan 10;14:100295
pubmed: 35036983
Aging Clin Exp Res. 2007 Oct;19(5):390-3
pubmed: 18007117
Respir Med. 2007 Sep;101(9):1845-63
pubmed: 17544265
Euro Surveill. 2020 May;25(19):
pubmed: 32431289
Lancet Psychiatry. 2021 Sep;8(9):797-812
pubmed: 34274033
Front Immunol. 2021 Aug 31;12:720952
pubmed: 34531867
Rev Neurol (Paris). 2022 Jan-Feb;178(1-2):129-136
pubmed: 34556345
J Neurol Sci. 2021 Sep 15;428:117610
pubmed: 34384971
Dement Geriatr Cogn Disord. 2021;50(5):425-436
pubmed: 34856552
Can J Psychiatry. 2017 Mar;62(3):170-181
pubmed: 28212496
Lancet Neurol. 2020 Nov;19(11):892
pubmed: 33098796
Int J Environ Res Public Health. 2021 Apr 06;18(7):
pubmed: 33917578
Lancet Public Health. 2022 Feb;7(2):e105-e125
pubmed: 34998485
Sci Rep. 2021 Jun 15;11(1):12530
pubmed: 34131216
Alzheimers Dement (Amst). 2020 Nov 14;12(1):e12114
pubmed: 33225041
Front Psychiatry. 2020 Oct 06;11:573367
pubmed: 33132936
Alzheimers Dement. 2020 Nov;16(11):1571-1581
pubmed: 32789951
J Alzheimers Dis. 2021;84(4):1447-1452
pubmed: 34690147
J Alzheimers Dis. 2020;78(4):1775-1782
pubmed: 33285638
Nat Commun. 2020 Dec 9;11(1):6317
pubmed: 33298944
Nat Rev Neurol. 2021 Feb;17(2):69-70
pubmed: 33408384
J Alzheimers Dis. 2021;84(3):1173-1181
pubmed: 34542068
J Alzheimers Dis Rep. 2018 Feb 2;2(1):1-26
pubmed: 30480245
Lancet. 2020 Apr 11;395(10231):1190-1191
pubmed: 32240625
J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2224-2230
pubmed: 32687551
Int J Infect Dis. 2020 Oct;99:47-56
pubmed: 32721533
Public Health. 2021 Jan;190:108-115
pubmed: 33412438
Alzheimers Res Ther. 2021 Apr 10;13(1):77
pubmed: 33838684
PLoS One. 2020 Nov 17;15(11):e0241955
pubmed: 33201896
Lancet Public Health. 2018 Jul;3(7):e323-e332
pubmed: 29908859
EClinicalMedicine. 2020 Sep;26:100524
pubmed: 32864594
Infection. 2021 Feb;49(1):15-28
pubmed: 32860214
Front Public Health. 2020 Apr 29;8:152
pubmed: 32411652